CTT Pharma officer buys 9,800 shares at $0.0489

A reporting officer of CTT Pharmaceutical Holdings, Inc. increased direct ownership through a modest open-market or private purchase.

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. (CTTH), acting in a reporting officer capacity, reported a purchase of 9,800 shares of CTTH common stock on September 4, 2026 at $0.0489 per share. Following this open-market or private transaction, direct holdings increased to 9,397,056 shares.

Insider Trade Summary

Net Buyer: 9,800 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 9,800 shs ($479.22)

Type	Security	Shares	Price	Value
Purchase	CTTH	9,800	$0.0489	$479.22

Holdings After Transaction: CTTH — 9,397,056 shares (Direct)

Key Figures

Shares purchased: 9,800 shares Purchase price per share: $0.0489 per share Shares owned after transaction: 9,397,056 shares +1 more

4 metrics

Shares purchased 9,800 shares Common stock purchased on September 4, 2026

Purchase price per share $0.0489 per share Price paid for CTTH shares on September 4, 2026

Shares owned after transaction 9,397,056 shares Direct ownership following the September 4, 2026 purchase

Net buy shares 9,800 shares Net effect of reported transactions in this Form 4

Key Terms

open market, private transaction, direct ownership

3 terms

open market market

"Purchase in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

private transaction market

"Purchase in open market or private transaction"

A private transaction is the sale or transfer of securities, assets, or ownership stakes carried out directly between a small number of parties rather than on a public exchange. For investors it matters because these deals are less visible and often less liquid than public trades, so pricing can be harder to verify, the investment can be harder to sell quickly, and buyers or sellers may gain strategic advantages not available in open markets — like negotiated terms similar to a private garage sale versus a crowded marketplace.

direct ownership financial

"direct holdings increased to 9,397,056 shares"

FAQ

What insider transaction did CTTH report in this Form 4?

CTT Pharmaceutical Holdings, Inc. reported a purchase of 9,800 CTTH shares on September 4, 2026, classified as a purchase in an open market or private transaction.

At what price were the CTTH shares purchased in this Form 4?

The reported transaction shows a purchase price of $0.0489 per share for the 9,800 CTTH shares acquired on September 4, 2026.

How many CTTH shares are held after this insider purchase?

After the reported purchase, direct ownership stands at 9,397,056 CTTH shares, as disclosed in the Form 4 data.

Is the CTTH insider transaction part of a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox as not affirmed, meaning the reported purchase is not stated to be pursuant to a Rule 10b5-1 trading plan.

What type of security was involved in the CTTH Form 4 transaction?

The transaction involves CTTH common stock, with 9,800 shares purchased and direct ownership reported after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:18 PM Accepted by SEC EDGAR 09/04/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	09/04/2026		P		9,800	A	$0.0489	9,397,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)